跳转至内容
Merck
CN

454202

8-Methoxymethyl-3-isobutyl-1-methylxanthine

A cell-permeable selective inhibitor of Ca2+-calmodulin-dependent phosphodiesterase (PDE I; IC50 = 4 µM).

别名:

8-Methoxymethyl-3-isobutyl-1-methylxanthine, 8-Methoxymethyl-IBMX

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C12H18N4O3
化学文摘社编号:
分子量:
266.30
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (TLC)
Form:
solid
Quality level:
Storage condition:
OK to freeze
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


Quality Level

assay

≥98% (TLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze

color

white

solubility

ethanol: 2 mg/mL, DMSO: 5 mg/mL

shipped in

ambient

storage temp.

10-30°C

SMILES string

[nH]1c2c(nc1COC)N(C(=O)N(C2=O)C)CC(C)C

InChI

1S/C12H18N4O3/c1-7(2)5-16-10-9(11(17)15(3)12(16)18)13-8(14-10)6-19-4/h7H,5-6H2,1-4H3,(H,13,14)

InChI key

NBLBCGUCPBXKOV-UHFFFAOYSA-N

General description

A cell-permeable selective inhibitor of Ca2+-calmodulin-dependent phosphodiesterase (PDE I; IC50 = 4 µM).
A cell-permeable, selective inhibitor of Ca2+-calmodulin-dependent phosphodiesterase (PDE I, IC50 = 4 µM).

Biochem/physiol Actions

Cell permeable: yes
Primary Target
PDE 1
Product does not compete with ATP.
Reversible: no
Target IC50: 4 µM against Ca2+-calmodulin-dependent phosphodiesterase (PDE I)

Preparation Note

Following reconstitution aliquot and freeze at -20°C. Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Jackson, E.K., et al. 1997. J. Cardiovasc. Pharmacol. 30, 798.
Ahn, H.S., et al. 1989. Biochem. Pharmacol.38, 3331.
Han, P., et al. 1989. J. Biol. Chem.274, 22337.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)


Still not finding the right product?

Explore all of our products under


存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



E K Jackson et al.
Journal of cardiovascular pharmacology, 30(6), 798-801 (1998-01-22)
The objective this investigation was to determine the relative importance of type I, III, and IV phosphodiesterases in the regulation of cyclic adenosine monophosphate (cAMP) in the renal circulation. In the first experimental series, four groups of isolated rat kidneys
H S Ahn et al.
Biochemical pharmacology, 38(19), 3331-3339 (1989-10-01)
In this study three forms of cyclic nucleotide phosphodiesterase (PDE) isolated from rabbit aorta were pharmacologically characterized, and the consequence of selective inhibition of calmodulin-stimulated PDE (CaM-PDE) and cGMP specific PDE (cG-PDE) was evaluated using PDE inhibitors. The cG-PDE (F1)



全球贸易项目编号

货号GTIN
454202-10MG04055977204742